Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2025)

Eton Pharmaceuticals' Cost of Revenue history spans 7 years, with the latest figure at $21.3 million for Q3 2025.

  • For Q3 2025, Cost of Revenue rose 430.83% year-over-year to $21.3 million; the TTM value through Sep 2025 reached $34.2 million, up 142.35%, while the annual FY2024 figure was $15.6 million, 47.43% up from the prior year.
  • Cost of Revenue for Q3 2025 was $21.3 million at Eton Pharmaceuticals, up from $7.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $21.3 million in Q3 2025 and bottomed at $136000.0 in Q2 2021.
  • The 5-year median for Cost of Revenue is $2.1 million (2022), against an average of $3.3 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 1458.82% in 2021 before it crashed 77.19% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $447000.0 in 2021, then soared by 378.3% to $2.1 million in 2022, then surged by 72.26% to $3.7 million in 2023, then surged by 40.4% to $5.2 million in 2024, then skyrocketed by 312.88% to $21.3 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Cost of Revenue are $21.3 million (Q3 2025), $7.0 million (Q2 2025), and $675000.0 (Q1 2025).